Compare XEL & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | EW |
|---|---|---|
| Founded | 1909 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2B | 50.2B |
| IPO Year | 2003 | 1999 |
| Metric | XEL | EW |
|---|---|---|
| Price | $81.97 | $85.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | $84.36 | ★ $96.47 |
| AVG Volume (30 Days) | 4.4M | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.42 | 1.83 |
| Revenue | ★ $11,537,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $9.67 | $13.39 |
| Revenue Next Year | $8.02 | $9.78 |
| P/E Ratio | ★ $24.13 | $44.69 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $65.21 | $65.94 |
| 52 Week High | $84.23 | $87.89 |
| Indicator | XEL | EW |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 57.77 |
| Support Level | $71.95 | $81.04 |
| Resistance Level | $82.51 | $87.22 |
| Average True Range (ATR) | 1.36 | 2.11 |
| MACD | -0.25 | 0.32 |
| Stochastic Oscillator | 56.49 | 80.65 |
Xcel Energy manages utilities serving 3.9 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.